Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,462 total articles
RadNet, Inc., a leading US outpatient diagnostic imaging provider, announced its intention to secure a $200 million incremental term loan. This funding aims to support future acquisitions, organic expansion, health system partnerships, and other corporate purposes to accelerate strategic growth across its national imaging network and technology pla…
Diginex Limited announced the extension of the long stop date to June 12, 2026 for its proposed acquisition of Resulticks Global Companies Pte. Limited. The acquisition aims to significantly expand Diginex's platform by integrating ESG data with real-time decisioning and customer engagement capabilities. Resulticks is expected to bring approximatel…
WTW (NASDAQ: WTW), a global advisory and solutions firm, has received approval from the Dubai Financial Services Authority to operate as WTW Investments (DIFC) Limited in Dubai International Financial Centre. This licence enables WTW to offer regulated investment advisory services and fund solutions locally, marking a strategic expansion in the gro…
NewAmsterdam Pharma announced multiple presentations at the National Lipid Association 2026 Scientific Sessions showcasing data on obicetrapib, their novel oral low-dose CETP inhibitor for hypercholesterolemia treatment. The presentations cover efficacy, safety, and potential cardiovascular benefits based on extensive Phase 2 and 3 clinical trials.…
Lexicon Pharmaceuticals announced presentations of clinical study data for sotagliflozin in Type 1 diabetes and pilavapadin in diabetic peripheral neuropathic pain at the 2026 ADA Scientific Sessions. Sotagliflozin, an oral SGLT1/2 inhibitor, shows continued potential ahead of a planned NDA resubmission in mid-2026. Pilavapadin, targeting neuropath…
Integer Holdings Corporation, a leading medical device contract development and manufacturing organization, announced its participation in the Truist Securities 2026 MedTech Conference on June 16, 2026. The company's executive leadership team will engage in a fireside chat, and the event will be webcast live for investors and stakeholders.
CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to advance conditionally activated bispecific immunotherapies utilizing CytomX's PROBODY platform and Regeneron's Veloci-Bi technology. The expanded deal includes a $37 million target selection payment and potential milestones totaling approximately $4 billion as Rege…
Spyre Therapeutics has completed enrollment for all sub-studies in its SKYWAY basket trial evaluating SPY072, an anti-TL1A antibody, across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The company reaffirms expected clinical data readouts in Q3 2026 for RA and Q4 2026 for PsA and axSpA, supporting poten…
Westwood Holdings Group (NYSE: WHG) disclosed monthly income distributions for three ETFs—Westwood Salient Enhanced Midstream Income ETF (MDST), Westwood Salient Enhanced Energy Income ETF (WEEI), and Westwood Enhanced Income Opportunity (YLDW). These actively managed funds provide monthly income through a combination of dividends and covered call …
Kyverna Therapeutics announced updated data from the Phase 1 portion of its COMPARE trial evaluating mivocabtagene autoleucel (miv-cel) in patients with active ACPA-positive, treatment-refractory rheumatoid arthritis. The data demonstrated deep B-cell depletion, sustained reduction in disease-associated autoantibodies, substantial reduction in dise…
Biomea Fusion announces a new research collaboration with the University of Leicester to evaluate the combination of its investigational menin inhibitor, icovamenib, with semaglutide in overweight and obese individuals. This randomized double-blind study aims to determine if icovamenib can enhance weight loss while preserving lean mass and improvin…
Grayscale Investments has introduced the Grayscale Hyperliquid Staking ETF (HYPG) on Nasdaq, providing investors with exposure to the HYPE token of the Hyperliquid protocol along with staking rewards. As the lowest gross fee Hyperliquid ETP in the US, HYPG aims to offer a cost-efficient way to invest in a rapidly growing decentralized finance ecosy…
Richtech Robotics Inc., listed on Nasdaq as RR, has completed the acquisition of a 79,325 square foot warehouse facility in Las Vegas for $21.2 million. This expansion is aimed at enhancing the company's AI infrastructure and robotics development, supporting its Industrial, Commercial, and Data Services strategic pillars. The facility will house GP…
Twin Disc, Inc., a manufacturer of marine and heavy-duty off-highway power transmission equipment, announced that its CFO Jeff Knutson will present at the Three Part Advisors East Coast IDEAS Conference on June 10, 2026, in New York. The company also offers one-on-one investor meetings at the event, aiming to engage with institutional investors and…
Aduro Clean Technologies has appointed Jan Lemmens as Project Director to lead the engineering, permitting, and construction preparation of its first-of-a-kind Hydrochemolytic™ chemical recycling facility at Chemelot Industrial Park, Netherlands. The facility, aimed at processing 10,000 tonnes of waste plastics annually, is a strategic initiative t…
Rent the Runway, Inc. announced its Q1 fiscal 2026 results, achieving $89.9 million in revenue, up 29.2% year-over-year, exceeding guidance. The company showed improvement in EBITDA margin and add-on revenue increased by 70.4% YoY. New interim leadership appointments were made, and the company highlighted AI-driven personalization enhancements to i…
Powerus and Swarmer have signed a Memorandum of Understanding to explore integration of Swarmer's vendor-agnostic autonomous swarming software with Powerus's air and maritime autonomous systems. The collaboration targets defense, counter-drone, border security, and critical infrastructure protection missions. The MOU focuses on technical evaluation…
Medicus Pharma announces the submission of Protocol SKNJCT-005 to the FDA for a Phase 2b open-label registrational study of SkinJect® in patients with Gorlin Syndrome, a rare genetic disorder characterized by multiple basal cell carcinomas. The study aims to generate efficacy and safety data supporting a future New Drug Application (NDA) for SkinJe…
Celularity Inc., a US-based regenerative and cellular medicine company, announced the appointment of Rick Gonzalez as Chief Commercial Officer. Gonzalez brings extensive leadership experience in biotechnology and healthcare commercialization, supporting Celularity's efforts to advance its placental-derived cellular therapies, including cenplacel-L …
VenHub Global, Inc. announced its support of the Culver City GoPass program, which has enabled over 56,000 free transit trips for K-12 students, benefiting nearly 600 active riders and saving families approximately $100,000 in transportation costs. The initiative aligns with VenHub's mission to connect communities by deploying autonomous Smart Stor…
Biogen announced presentations of 14 abstracts highlighting clinical data from its nephrology portfolio, including approved drug EMPAVELI (pegcetacoplan) and the investigational anti-CD38 antibody felzartamab, at the European Renal Association and American Transplant Congresses. The data show sustained efficacy and safety in treating rare kidney di…
Bread Financial Holdings announced its participation in the upcoming Morgan Stanley US Financials Conference, where CFO Perry Beberman will engage in a fireside chat. The company is showcasing its tech-forward financial services and payment solutions targeting millions of U.S. consumers, highlighting its 30 years of industry presence.
Dyne Therapeutics has completed enrollment of 71 participants in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial evaluating z-basivarsen (DYNE-101) for treatment of myotonic dystrophy type 1 (DM1). Topline data are anticipated in Q1 2027, supporting a potential U.S. Accelerated Approval submission by Q3 2027 and possible launch i…
TG Therapeutics announced favorable Phase 1 trial results for their high-concentration subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing good tolerability, sustained drug exposure, and comparable biological activity versus intravenous administration. The data bolster confidence in the ongoing Phase 3 trial evaluating quarterly subcuta…
Palvella Therapeutics has completed a pre-New Drug Application meeting with the FDA for its investigational drug QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations, a serious and chronic vascular malformation with no current FDA-approved treatment. The company remains on track to submit its NDA in the second half of 2026 and p…
